Drug Rhythm-Control Failure Widens Opening For Ablation, Say Cardiologists
This article was originally published in The Gray Sheet
Executive Summary
Drug-based rhythm-control therapy does not help keep patients with atrial fibrillation and heart failure alive any better than conventional heart failure drugs, researchers report in the June 19 New England Journal of Medicine
You may also be interested in...
J&J Gets Panel Date Seeking First A-Fib Ablation Catheter Indication
Johnson & Johnson's chances of becoming the first firm to market an ablation device in the U.S. labeled for treating atrial fibrillation will be clearer next month, when the company is scheduled to present PMA supplement data to an FDA advisory panel
J&J Gets Panel Date Seeking First A-Fib Ablation Catheter Indication
Johnson & Johnson's chances of becoming the first firm to market an ablation device in the U.S. labeled for treating atrial fibrillation will be clearer next month, when the company is scheduled to present PMA supplement data to an FDA advisory panel
CMS Floats Topics For Possible National Coverage Determinations
Off-label procedures with drug-eluting stents, atrial fibrillation ablation and minimally invasive bariatric surgery are among topics CMS is considering for future national coverage policy determinations, the agency said July 30